CKD Progression Risk Up With Increasing Albuminuria in Normal Range
By Elana Gotkine HealthDay Reporter
MONDAY, April 1, 2024 -- For people with chronic kidney disease (CKD) and normoalbuminuria, the risk for CKD progression increases with higher levels of albuminuria, according to a study published online April 2 in the Annals of Internal Medicine.
Ashish Verma, M.B., B.S., from the Boston University Chobanian & Avedisian School of Medicine, and colleagues estimated the increase in the cumulative incidence of CKD progression with higher baseline levels of albuminuria among persons with CKD who had normoalbuminuria (<30 mg/g) in a multicenter prospective study. Data were included for 1,629 participants meeting criteria from the Chronic Renal Insufficiency Cohort study with CKD and a urine albumin-creatinine ratio (UACR) <30 mg/g.
The researchers found that 182 of the participants experienced CKD progression during a median follow-up of 9.8 years. For UACR levels of 0 to <5, 5 to <15, and ≥15 mg/g, the 10-year adjusted cumulative incidences of CKD progression were 8.7, 11.5, and 19.5 percent, respectively. The absolute risk differences were 7.9 and 10.7 percent comparing persons with UACR ≥15 mg/g to those with UACR of 5 to <15 and 0 to <5 mg/g, respectively. There was a linear increase observed in 10-year adjusted cumulative incidence based on baseline UACR levels.
"These findings underscore the need for future studies to determine the optimal threshold for initiating treatment with antiproteinuric agents and whether the further reduction in albuminuria may improve adverse clinical outcomes in persons with CKD who have normoalbuminuria," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
ACG: 2000 to 2022 Saw Rise in Early-Onset CRC Mortality in the United States
THURSDAY, Oct. 31, 2024 -- Early-onset colorectal cancer (EO-CRC) mortality rose in the United States over the past two decades, most notably in patients aged 20 to 44 years...
Cell-Free Blood DNA Tests Less Effective Than Other CRC Screening
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other screening modalities...
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.